NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry
NAMI-A ((ImH)[trans-RuCl4 (dmso-S)(Im)], Im= imidazole) and KP1019/1339
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …
(KP1019=(IndH)[trans-RuCl4 (Ind) 2], Ind= indazole; KP1339= Na [trans-RuCl4 (Ind) 2]) are …
Metal-based drugs that break the rules
CS Allardyce, PJ Dyson - Dalton transactions, 2016 - pubs.rsc.org
Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers
and are applied in the majority of anticancer chemotherapeutic regimens. The success of …
and are applied in the majority of anticancer chemotherapeutic regimens. The success of …
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
S Leijen, SA Burgers, P Baas, D Pluim, M Tibben… - Investigational new …, 2015 - Springer
Summary Background This phase I/II study determined the maximal tolerable dose, dose
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …
limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of …
Redox activation of metal-based prodrugs as a strategy for drug delivery
N Graf, SJ Lippard - Advanced drug delivery reviews, 2012 - Elsevier
This review provides an overview of metal-based anticancer drugs and drug candidates. In
particular, we focus on metal complexes that can be activated in the reducing environment of …
particular, we focus on metal complexes that can be activated in the reducing environment of …
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …
two of them have entered clinical trials. Compared to platinum drugs, the complexes based …
Non platinum metal complexes as anti‐cancer drugs
I Ott, R Gust - Archiv der Pharmazie: An International Journal …, 2007 - Wiley Online Library
The development of metal complexes with platinum central atoms such as cisplatin or
carboplatin had an enormous impact on current cancer chemotherapy. However, the …
carboplatin had an enormous impact on current cancer chemotherapy. However, the …
Recent developments in ruthenium anticancer drugs
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH+)[RuIIICl4
(Im)(S-dmso)], where Im= imidazole and S-dmso= S-bound dimethylsulfoxide) or KP1019 …
(Im)(S-dmso)], where Im= imidazole and S-dmso= S-bound dimethylsulfoxide) or KP1019 …
Ruthenium complexes as anticancer agents
I Kostova - Current medicinal chemistry, 2006 - ingentaconnect.com
Cancer is one of the major cases of death in the world. Current treatment of cancer is limited
to surgery, radiotherapy, and the use of cytotoxic agents, despite their well known side …
to surgery, radiotherapy, and the use of cytotoxic agents, despite their well known side …
Linking the future of anticancer metal-complexes to the therapy of tumour metastases
Cancer chemotherapy is almost always applied to patients with one or more diagnosed
metastases and is expected to impact these lesions, thus providing significant benefits to the …
metastases and is expected to impact these lesions, thus providing significant benefits to the …
Structure− activity relationships for cytotoxic ruthenium (II) arene complexes containing N, N-, N, O-, and O, O-chelating ligands
A Habtemariam, M Melchart, R Fernández… - Journal of medicinal …, 2006 - ACS Publications
We report structure− activity relationships for organometallic RuII complexes of the type [(η6-
arene) Ru (XY) Cl] Z, where XY is an N, N-(diamine), N, O-(eg, amino acidate), or O, O-(eg, β …
arene) Ru (XY) Cl] Z, where XY is an N, N-(diamine), N, O-(eg, amino acidate), or O, O-(eg, β …